Higher Ozempic Dose Linked to Lower Heart Risk Compared to Mounjaro

Recent research indicates that increasing the dosage of Ozempic may be associated with a reduced risk of major adverse cardiovascular events (MACE) compared to switching to Mounjaro. This finding comes from a comprehensive analysis presented at the European Association for the Study of Diabetes Annual Meeting in Milan, Italy, which examined real-world data from over 636,000 adults with type 2 diabetes.

The study, known as the COMPETE SWITCH Cardiovascular analysis, focused on two groups: 185,705 individuals who increased their weekly Ozempic dosage from 1 mg to 2 mg, and 23,104 participants who switched to Mounjaro. The results revealed that those who escalated their Ozempic dosage exhibited a 6% lower risk of experiencing MACE—an umbrella term that includes all-cause mortality, heart attacks, and strokes—compared to those who opted for Mounjaro.

At the beginning of the study, all participants were receiving a 1 mg weekly dose of Ozempic. Over the course of 720 days, the analysis noted that 67.2% of individuals remained on the initial 1 mg dose, while 29.2% increased to 2 mg, and a small percentage, 3.6%, switched to Mounjaro. By the end of the follow-up period, the numbers slightly shifted, with 57.4% still on the 1 mg dose, 36.9% having increased to 2 mg, and 5.7% switching to Mounjaro.

While these findings are promising, experts caution that the study is observational, indicating an association rather than a definitive cause-and-effect relationship. Dr. Mir Ali, the medical director of MemorialCare Surgical Weight Loss Center, emphasized the importance of medication adherence, noting that switching medications can complicate treatment and impact patient outcomes.

Furthermore, the precise reasons for the differences in cardiovascular risk between the two medications remain unclear. Dr. Ali suggested that factors such as weight loss and the direct effects of these drugs on metabolic hormones could play a role.

Ozempic (semaglutide) and Mounjaro (tirzepatide) belong to a class of medications known as GLP-1 receptor agonists, which are used in the management of type 2 diabetes. While both medications have similar mechanisms of action, they differ in their receptor targets. Ozempic is a direct GLP-1 receptor agonist, while Mounjaro acts on both GLP-1 and GIP receptors. This distinction may result in varying effects on individual patients.

For those considering a switch from Ozempic to Mounjaro, it is crucial to consult with healthcare providers. Dr. Blumfield from Manhattan Cardiology advises that changes in medication should only be made if there are significant tolerance issues with one drug. He emphasized that if a patient is effectively managing their diabetes and weight with Ozempic, there may be no need to switch.

GLP-1 medications can have side effects such as nausea, vomiting, and gastrointestinal issues, but these are typically mild and may diminish over time. It’s essential for patients to discuss any concerns with their healthcare professionals to determine the most suitable treatment plan for their individual health needs.

As research continues, more insights will emerge regarding the cardiovascular safety and efficacy of these medications, helping patients and